Pfizer’s reset year starts with a little profit

Off addiction, Biotech, biotechnology, Business, drug development, drug prices, drug pricing, genetics, Health, Human Health, Life Sciences, Medicine, opioids, Pharma, Pharmaceuticals, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the final act in a pharmaceutical saga, the debate of Vertex Pharmaceuticals’ success, and news on 23andMe’s ongoing transformation.

Read the rest…

Read Original Article: Pfizer’s reset year starts with a little profit »

About The Author